Advancements in technology and medical science have played a key role in the development of new treatments and therapies for an array of disorders and diseases. Conventionally, primary immunodeficiencies have been predominantly characterized as per the immunologic phenotype. Research and development activities within the primary immunodeficiency market are largely focused on the discovery of human genes that could cause primary immunodeficiency. More recently, four distinct genetic defects that could potentially lead to primary immunodeficiency diseases and acute congenital neutropenia continue to drive research in the primary immunodeficiency market.
Some of the key areas within the primary immunodeficiency market that are currently being investigated include the role of follicular T cells in the development of antibody responses, the link between impaired B-cell maturation and inflammatory conditions, inflammatory and autoimmune manifestations, and recently discovered gene defects. Moreover, several researchers are exploring the overall efficacy of the lentiviral vector-mediated gene therapies in patients that are suffering from adenosine deaminize-deficient severe combined immunodeficiency (SCID). Over the past decade, the management of primary immunodeficiency has advanced at a rapid pace due to a surge in investments and focus on research. Strides taken by sequencing, gene-editing tools, and the development of new drugs are expected to boost the prospects of the market for primary immunodeficiency during the forecast period. At the back of these factors, the global primary immunodeficiency market is expected to attain reach a value of ~US$ 9.9 Bn by the end of 2028.
One of the most common symptomatic primary immunodeficiency disorders that continues to attract investments and research include the common variable immunodeficiency disorder. The onset of genome sequencing and soaring interest in genome-wide association studies have played a key role in enhancing and understanding the overall genetics of common variable primary immunodeficiency. Research has also opened up new frontiers as far as understanding the pathogenesis of common variable primary immunodeficiency. In recent times, the adoption of DNA sequencing, RNA sequencing, epigenetic, and proteomic profiles is on the rise to assess common variable primary immunodeficiency that is linked with disease pathways and other therapeutic targets. Scientists and researchers are increasingly focusing on understanding the genetics of primary immunodeficiency.
The prevalence of primary immunodeficiency around the world is on the rise due to which, the demand for novel treatments and therapies has witnessed considerable growth. Significant progress in sequencing technologies is triggered by the discovery of a range of monogenic forms of common variable primary immunodeficiency. Over the past decade, due to advancements in technology and research, participants of the primary immunodeficiency market are swaying toward the use of omics-based technologies and integrating next-generation platforms in the common variable primary immunodeficiency space.
Over the past few decades, inborn errors of immunity (IEIs) have witnessed exponential growth. In addition, over 400 glaring defects have been listed in the recently amended International Union of Immunological Societies (IUIS). In the past few years, due to considerable information pertaining to new genes and diseases, the primary immunodeficiency market is set to witness notable development and likely to emphasize on the concept of “inborn errors of immunity” as a collective group of various phenotypes such as infection, autoimmunity, autoinflammation, malignancy, allergy, etc. Developments in molecular studies have streamlined the detection of an array of potential targets for certain therapeutic interventions. Targeted therapies constitute small molecules and monoclonal antibodies, including cytokine inhibitors and cytokines. Some of the most popular and extensively used targeted therapies include rituximab— a therapy deployed to cater to issues related to autoimmune and lymph proliferative manifestations. Apart from noteworthy developments in molecular studies, gene therapies have also gained a great amount of popularity over the past three decades. The adoption of gene therapy in the primary immunodeficiency market has increased at a consistent pace since the 1990s, particularly to address X-SCID and ADA-SCID.
Although developments in molecular studies are expected to augment the market for primary immunodeficiency, companies in the current market landscape are expected to overcome a few major roadblocks, including increasing the availability of different diagnostic tools and treatments to patients across the world and offering customized treatments cost-effectively.
Analysts’ Viewpoint
The global primary immunodeficiency market is expected to grow at a healthy CAGR of ~6% during the forecast period. The market growth can be primarily attributed to a host of factors, including advancements in molecular studies, rapid strides taken by next-generation sequencing technologies, DNA sequencing, and RNA sequencing. Research and development activities will continue to play a key role in boosting the prospects of the new primary immunodeficiency treatment and therapies. Companies operating in the current market landscape should ideally focus on the development of tailor-made primary immunodeficiency therapies to gain an edge.
Primary immunodeficiency market is expected to attain reach a value of ~US$ 9.9 Bn by the end of 2028
Primary immunodeficiency market is projected to expand at a CAGR of ~6% from 2020 to 2028
Primary immunodeficiency market is driven by high prevalence of hypertension
North America accounted for a major share of the global primary immunodeficiency market
Key players in the global primary immunodeficiency market include Shire plc, CSL Behring, Kedrion Biopharma Inc, Grifols, S.A, Octapharma
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Primary Immunodeficiency Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Primary Immunodeficiency Market Analysis and Forecast, 2018–2028
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Regulatory Scenario by Region/globally
5.2. Pipeline Analysis
5.3. Primary Immunodeficiency Market Clinical Trials
6. Global Primary Immunodeficiency Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2018–2028
6.3.1. Antibody Deficiency
6.3.1.1. Agammaglobulinaemia
6.3.1.2. Common Variable Immune Deficiency
6.3.1.3. Selective IgA Deficiency
6.3.1.4. IgG Subclass Deficiency
6.3.1.5. Others
6.3.2. Cellular Deficiency
6.3.2.1. Ataxia Telangiectasia
6.3.2.2. Hyper IgM Syndromes
6.3.2.3. Wiskott-Aldrich Syndrome
6.3.2.4. DiGeorge Syndrome
6.3.2.5. Others
6.3.3. Innate Immune
6.3.3.1. Complement Deficiencies
6.3.3.2. Hyper IgE Syndrome
6.3.3.3. Others
6.4. Market Attractiveness, by Type
7. Global Primary Immunodeficiency Market Analysis and Forecast, by Treatment Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Treatment Type, 2018–2028
7.3.1. Immunoglobuline replacement Therapy
7.3.2. Antibiotic Therapy
7.3.3. Stem cell and Gene Therapy
7.3.4. Others (Vaccines, Nutritional Supplements, and Others)
7.4. Market Attractiveness, by Treatment Type
8. Global Primary Immunodeficiency Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region
9. North America Primary Immunodeficiency Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Type, 2018–2028
9.2.1. Antibody Deficiency
9.2.1.1. Agammaglobulinaemia
9.2.1.2. Common Variable Immune Deficiency
9.2.1.3. Selective IgA Deficiency
9.2.1.4. IgG Subclass Deficiency
9.2.1.5. Others
9.2.2. Cellular Deficiency
9.2.2.1. Ataxia Telangiectasia
9.2.2.2. Hyper IgM Syndromes
9.2.2.3. Wiskott-Aldrich Syndrome
9.2.2.4. DiGeorge Syndrome
9.2.2.5. Others
9.2.3. Innate Immune
9.2.3.1. Complement Deficiencies
9.2.3.2. Hyper IgE Syndrome
9.2.3.3. Others
9.3. Market Value Forecast, by Treatment Type, 2018–2028
9.3.1. Immunoglobuline replacement Therapy
9.3.2. Antibiotic Therapy
9.3.3. Stem cell and Gene Therapy
9.3.4. Others (Vaccines, Nutritional Supplements, and Others)
9.4. Market Value Forecast, by Country, 2018–2028
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Type
9.5.2. By Treatment Type
9.5.3. By Country
10. Europe Primary Immunodeficiency Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2018–2028
10.2.1. Antibody Deficiency
10.2.1.1. Agammaglobulinaemia
10.2.1.2. Common Variable Immune Deficiency
10.2.1.3. Selective IgA Deficiency
10.2.1.4. IgG Subclass Deficiency
10.2.1.5. Others
10.2.2. Cellular Deficiency
10.2.2.1. Ataxia Telangiectasia
10.2.2.2. Hyper IgM Syndromes
10.2.2.3. Wiskott-Aldrich Syndrome
10.2.2.4. DiGeorge Syndrome
10.2.2.5. Others
10.2.3. Innate Immune
10.2.3.1. Complement Deficiencies
10.2.3.2. Hyper IgE Syndrome
10.2.3.3. Others
10.3. Market Value Forecast, by Treatment Type, 2018–2028
10.3.1. Immunoglobuline Replacement Therapy
10.3.2. Antibiotic Therapy
10.3.3. Stem cell and Gene Therapy
10.3.4. Others (Vaccines, Nutritional Supplements, and Others)
10.4. Market Value Forecast, by Country/Sub-region, 2018–2028
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Type
10.5.2. By Treatment Type
10.5.3. By Country/Sub-region
11. Asia Pacific Primary Immunodeficiency Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2018–2028
11.2.1. Antibody Deficiency
11.2.1.1. Agammaglobulinaemia
11.2.1.2. Common Variable Immune Deficiency
11.2.1.3. Selective IgA Deficiency
11.2.1.4. IgG Subclass Deficiency
11.2.1.5. Others
11.2.2. Cellular Deficiency
11.2.2.1. Ataxia Telangiectasia
11.2.2.2. Hyper IgM Syndromes
11.2.2.3. Wiskott-Aldrich Syndrome
11.2.2.4. DiGeorge Syndrome
11.2.2.5. Others
11.2.3. Innate Immune
11.2.3.1. Complement Deficiencies
11.2.3.2. Hyper IgE Syndrome
11.2.3.3. Others
11.3. Market Value Forecast, by Treatment Type, 2018–2028
11.3.1. Immunoglobuline replacement Therapy
11.3.2. Antibiotic Therapy
11.3.3. Stem cell and Gene Therapy
11.3.4. Others (Vaccines, Nutritional Supplements, and Others)
11.4. Market Value Forecast, by Country/Sub-region, 2018–2028
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Type
11.5.2. By Treatment Type
11.5.3. By Country/Sub-region
12. Latin America Primary Immunodeficiency Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2018–2028
12.2.1. Antibody Deficiency
12.2.1.1. Agammaglobulinaemia
12.2.1.2. Common Variable Immune Deficiency
12.2.1.3. Selective IgA Deficiency
12.2.1.4. IgG Subclass Deficiency
12.2.1.5. Others
12.2.2. Cellular Deficiency
12.2.2.1. Ataxia Telangiectasia
12.2.2.2. Hyper IgM Syndromes
12.2.2.3. Wiskott-Aldrich Syndrome
12.2.2.4. DiGeorge Syndrome
12.2.2.5. Others
12.2.3. Innate Immune
12.2.3.1. Complement Deficiencies
12.2.3.2. Hyper IgE Syndrome
12.2.3.3. Others
12.3. Market Value Forecast, by Treatment Type, 2018–2028
12.3.1. Immunoglobuline Replacement Therapy
12.3.2. Antibiotic Therapy
12.3.3. Stem cell and Gene Therapy
12.3.4. Others (Vaccines, Nutritional Supplements, and Others)
12.4. Market Value Forecast, by Country/Sub-region, 2018–2028
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Type
12.5.2. By Treatment Type
12.5.3. By Country/Sub-region
13. Middle East & Africa Primary Immunodeficiency Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2018–2028
13.2.1. Antibody Deficiency
13.2.1.1. Agammaglobulinaemia
13.2.1.2. Common Variable Immune Deficiency
13.2.1.3. Selective IgA Deficiency
13.2.1.4. IgG Subclass Deficiency
13.2.1.5. Others
13.2.2. Cellular Deficiency
13.2.2.1. Ataxia Telangiectasia
13.2.2.2. Hyper IgM Syndromes
13.2.2.3. Wiskott-Aldrich Syndrome
13.2.2.4. DiGeorge Syndrome
13.2.2.5. Others
13.2.3. Innate Immune
13.2.3.1. Complement Deficiencies
13.2.3.2. Hyper IgE Syndrome
13.2.3.3. Others
13.3. Market Value Forecast, by Treatment Type, 2018–2028
13.3.1. Immunoglobuline replacement Therapy
13.3.2. Antibiotic Therapy
13.3.3. Stem cell and Gene Therapy
13.3.4. Others (Vaccines, Nutritional Supplements, and Others)
13.4. Market Value Forecast, by Country/Sub-region, 2018–2028
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Type
13.5.2. By Treatment Type
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis, by Company (2018)
14.3. Company Profiles
14.3.1. Shire
14.3.1.1. Company Overview
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. CSL Behring
14.3.2.1. Company Overview
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Kedrion Biopharma Inc.
14.3.3.1. Company Overview
14.3.3.2. Company Financials
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Grifols, S.A.
14.3.4.1. Company Overview
14.3.4.2. Company Financials
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Octapharma
14.3.5.1. Company Overview
14.3.5.2. Company Financials
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. China Biologic Products Holdings, Inc.
14.3.6.1. Company Overview
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Biotest AG
14.3.7.1. Company Overview
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Sanquin
14.3.8.1. Company Overview
14.3.8.2. Company Financials
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
14.3.9. LFB SA
14.3.9.1. Company Overview
14.3.9.2. Company Financials
14.3.9.3. Growth Strategies
14.3.9.4. SWOT Analysis
14.3.10. Other Prominent Key Players
List of Tables
Table: 1 Global Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Type, 2018–2028
Table: 2 Global Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Antibody Deficiency, 2018–2028
Table: 3 Global Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Cellular Deficiency, 2018–2028
Table: 4 Global Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Innate Immune, 2018–2028
Table: 5 Global Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2028
Table: 6 Global Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Region, 2018–2028
Table: 7 North America Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Type, 2018–2028
Table: 8 North America Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Antibody Deficiency, 2018–2028
Table: 9 North America Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Cellular Deficiency, 2018–2028
Table: 10 North America Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Innate Immune, 2018–2028
Table: 11 North America Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Treatment Type, 2018–2028
Table: 12 North America Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Country, 2018–2028
Table: 13 Europe Primary Immunodeficiency Market Revenue (US$ Mn) Forecast, by Type, 2018–2028
Table: 14 Europe Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Antibody Deficiency, 2018–2028
Table: 15 Europe Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Cellular Deficiency, 2018–2028
Table: 16 Europe Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Innate Immune, 2018–2028
Table: 17 Europe Primary Immunodeficiency Market Revenue (US$ Mn) Forecast, by Treatment Type, 2018–2028
Table: 18 Europe Primary Immunodeficiency Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2028
Table: 19 Asia Pacific Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Type, 2018–2028
Table: 20 Asia Pacific Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Antibody Deficiency, 2018–2028
Table: 21 Asia Pacific Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Cellular Deficiency, 2018–2028
Table: 22 Asia Pacific Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Innate Immune, 2018–2028
Table: 23 Asia Pacific Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Treatment Type, 2018–2028
Table: 24 Asia Pacific Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2028
Table: 25 Latin America Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Type, 2018–2028
Table: 26 Latin America Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Antibody Deficiency, 2018–2028
Table: 27 Latin America Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Cellular Deficiency, 2018–2028
Table: 28 Latin America Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Innate Immune, 2018–2028
Table: 29 Latin America Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2028
Table: 30 Latin America Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2028
Table: 31 Middle East & Africa Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Type, 2018–2028
Table: 32 Middle East & Africa Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Antibody Deficiency, 2018–2028
Table: 33 Middle East & Africa Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Cellular Deficiency, 2018–2028
Table: 34 Middle East & Africa Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Innate Immune, 2018–2028
Table: 35 Middle East & Africa Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Treatment Type, 2018–2028
Table: 36 Middle East & Africa Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2028
List of Figures
Figure: 1 Market Value, by Type (US$ Mn), 2018
Figure: 2 Market Share, Top Trends by Type (2018)
Figure: 3 Market Share by Region, 2018
Figure: 4 Market Share Analysis, by Region
Figure: 5 Porter’s Five Forces Analysis
Figure: 6 Global Primary Immunodeficiency Market Value (US$ Mn) and Forecast, 2019–2028
Figure: 7 Global Market Value Share, by Type (2018)
Figure: 8 Global Market Value Share, by Treatment Type (2018)
Figure: 9 Global Primary Immunodeficiency Market Value Share Analysis, by Type, 2018 and 2028
Figure: 10 Global Primary Immunodeficiency Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antibody Deficiency, 2018–2028
Figure: 11 Global Primary Immunodeficiency Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cellular Deficiency, 2018–2028
Figure: 12 Global Primary Immunodeficiency Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Innate Immune, 2018–2028
Figure: 13 Global Primary Immunodeficiency Market Attractiveness Analysis, by Type, 2019–2028
Figure: 14 Global Primary Immunodeficiency Market Value Share Analysis, by Treatment Type, 2018 and 2028
Figure: 15 Global Primary Immunodeficiency Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Immunoglobuline Replacement Therapy, 2018–2028
Figure: 16 Global Primary Immunodeficiency Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antibiotic Therapy, 2018–2028
Figure: 17 Global Primary Immunodeficiency Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Stem cell and Gene Therapy, 2018–2028
Figure: 18 Global Primary Immunodeficiency Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others (Vaccines, Nutritional Supplements and others), 2018–2028
Figure: 19 Global Primary Immunodeficiency Market Attractiveness Analysis, by Treatment Type, 2019–2028
Figure: 20 Global Primary Immunodeficiency Market Value Share Analysis, by Region, 2018 and 2028
Figure: 21 Global Primary Immunodeficiency Market Attractiveness Analysis, by Region, 2019–2028
Figure: 22 North America Primary Immunodeficiency Market Value (US$ Mn) Forecast, 2018–2028
Figure: 23 North America Primary Immunodeficiency Market Attractiveness Analysis, by Country, 2019–2028
Figure: 24 North America Primary Immunodeficiency Market Value Share Analysis, by Type, 2018 and 2028
Figure: 25 North America Primary Immunodeficiency Market Value Share Analysis, by Treatment Type, 2018 and 2028
Figure: 26 North America Primary Immunodeficiency Market Value Share Analysis, by Country, 2018 and 2028
Figure: 27 North America Primary Immunodeficiency Market Attractiveness Analysis, by Type, 2019-2028
Figure: 28 North America Primary Immunodeficiency Market Attractiveness Analysis, by Treatment Type, 2019-2028
Figure: 29 Europe Primary Immunodeficiency Market Value (US$ Mn) Forecast, 2018–2028
Figure: 30 Europe Primary Immunodeficiency Market Attractiveness Analysis, by Country/Sub-region, 2019–2028
Figure: 31 Europe Primary Immunodeficiency Market Value Share Analysis, by Type, 2018 and 2028
Figure: 32 Europe Primary Immunodeficiency Market Value Share Analysis, by Treatment Type, 2018 and 2028
Figure: 33 Europe Primary Immunodeficiency Market Value Share Analysis, by Country/Sub-region, 2018 and 2028
Figure: 34 Europe Primary Immunodeficiency Market Attractiveness Analysis, by Type, 2019-2028
Figure: 35 Europe Primary Immunodeficiency Market Attractiveness Analysis, by Treatment Type, 2019-2028
Figure: 36 Asia Pacific Primary Immunodeficiency Market Value (US$ Mn) Forecast, 2018–2028
Figure: 37 Asia Pacific Primary Immunodeficiency Market Attractiveness Analysis, by Country/Sub-region, 2019–2028
Figure: 38 Asia Pacific Primary Immunodeficiency Market Value Share Analysis, by Type, 2018 and 2028
Figure: 39 Asia Pacific Primary Immunodeficiency Market Value Share Analysis, by Treatment Type, 2018 and 2028
Figure: 40 Asia Pacific Primary Immunodeficiency Market Value Share Analysis, by Country/Sub-region, 2018 and 2028
Figure: 41 Asia Pacific Primary Immunodeficiency Market Attractiveness Analysis, by Type, 2019-2028
Figure: 42 Asia Pacific Primary Immunodeficiency Market Attractiveness Analysis, by Treatment Type, 2019-2028
Figure: 43 Latin America Primary Immunodeficiency Market Value (US$ Mn) Forecast, 2018–2028
Figure: 44 Latin America Primary Immunodeficiency Market Attractiveness Analysis, by Country/Sub-region, 2019–2028
Figure: 45 Latin America Primary Immunodeficiency Market Value Share Analysis, by Type, 2018 and 2028
Figure: 46 Latin America Primary Immunodeficiency Market Value Share Analysis, by Treatment Type, 2018 and 2028
Figure: 47 Latin America Primary Immunodeficiency Market Value Share Analysis, by Country/Sub-region, 2018 and 2028
Figure: 48 Latin America Primary Immunodeficiency Market Attractiveness Analysis, by Type, 2019-2028
Figure: 49 Latin America Primary Immunodeficiency Market Attractiveness Analysis, by Treatment Type, 2019-2028
Figure: 50 Middle East & Africa Primary Immunodeficiency Market Value (US$ Mn) Forecast, 2018–2028
Figure: 51 Middle East & Africa Primary Immunodeficiency Market Attractiveness Analysis, by Country/Sub-region, 2019–2028
Figure: 52 Middle East & Africa Primary Immunodeficiency Market Value Share Analysis, by Type, 2018 and 2028
Figure: 53 Middle East & Africa Primary Immunodeficiency Market Value Share Analysis, by Treatment Type, 2018 and 2028
Figure: 54 Middle East & Africa Primary Immunodeficiency Market Value Share Analysis, by Country/Sub-region, 2018 and 2028
Figure: 55 Middle East & Africa Primary Immunodeficiency Market Attractiveness Analysis, by Type, 2019-2028
Figure: 56 Middle East & Africa Primary Immunodeficiency Market Attractiveness Analysis, by Treatment Type, 2019-2028
Figure: 57 Shire PLC Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2017
Figure: 58 Shire PLC Research & Development Expenses (2017)
Figure: 59 Shire PLC Breakdown of Net Sales (% Share), by Business Segment (2017)
Figure: 60 Shire PLC Breakdown of Net Sales (% Share), by Region (2017)
Figure: 61 CSL Behring Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2018
Figure: 62 CSL Behring Research and Development Expenses, 2014-2018
Figure: 63 CSL Behring Breakdown of Net Sales (% Share), by Region (2017-2018)
Figure: 64 Kedrion Biopharma Inc Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2017
Figure: 65 Kedrion Biopharma Inc Research and Development Expenses, 2013-2017
Figure: 66 Kedrion Biopharma Inc Breakdown of Net Sales (% Share), by Business Segment (2017)
Figure: 67 Kedrion Biopharma Inc Breakdown of Net Sales (% Share), by Region (2017)
Figure: 68 Grifols, S. A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2017
Figure: 69 Grifols, S. A. Research and Development Expenses, 2013-2017
Figure: 70 Grifols, S. A. Breakdown of Net Sales (% Share), by Business Segment (2017)
Figure: 71 Grifols, S. A. Breakdown of Net Sales (% Share), by Region (2017)
Figure: 72 Octapharma Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2017
Figure: 73 Octapharma Research and Development Expenses, 2013-2017
Figure: 74 China Biologic Products Holdings, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2017
Figure: 75 China Biologic Products Holdings, Inc. Breakdown of Net Sales, by Business Segment, 2017
Figure: 76 China Biologic Products Holdings, Inc. Research & Development Cost, 2015–2017 (US$ Mn)
Figure: 77 Biotest AG Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2017
Figure: 78 Biotest AG Breakdown of Net Sales, by Country, 2017
Figure: 79 Biotest AG Breakdown of Net Sales, by business segment, 2017(US$ Mn)
Figure: 80 Sanquin Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure: 81 Sanquin Research & Development Expenses 2016 and 2017
Figure: 82 Sanquin Breakdown of Net Sales (% Share), by Business Segment (2017)
Figure: 83 Sanquin Breakdown of Net Sales (% Share), by Region (2017)
Figure: 84 LFB S.A. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure: 85 LFB S.A. Breakdown of Net Sales, by Region, 2016
Figure: 86 LFB S.A. Breakdown of Net Sales, by Business Segment, 2016
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Primary Immunodeficiency Market
